Report period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, С$ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
TELO:CN | Telo Genomics | Common share | - | CA87975M2085 | CA$0.115 |
Company name | Telo Genomics |
---|---|
Sector | Health Care / Health Care Equipment & Services / Health Care Technology / Health Care Technology |
Business address | MaRS Centre, South Tower 101 College Street, Suite 200 Toronto, ON M5G 1L7 Canada |
Mailing address | MaRS Centre, South Tower 101 College Street, Suite 200 Toronto, ON M5G 1L7 Canada |
Website | www.telodx.com |